Phase II Study of Bevacizumab, Capecitabine and Oxaliplatin in Colon Cancer

Asan Medical Center49 enrolled

Overview

The purpose of this study is to determine the efficacy and safety of bevacizumab/capecitabine/oxaliplatin combination in metastatic or recurrent Korean colorectal cancer.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Metastatic Colorectal Cancer

Interventions

BevacizumabDRUG

Bevacizumab, Capecitabine, Oxaliplatin

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically or cytologically documented colorectal adenocarcinoma * ECOG performance status of 2 or lower * Adequate bone marrow function * Adequate kidney function * Adequate liver function * Informed consent Exclusion Criteria: * Major surgical procedure or significant traumatic injury within 28 days prior to study treatment start * Known allergy to study drugs

Locations (6)

National Cancer Center

Goyang, South Korea

Asan Medical Center

Seoul, South Korea

Samsung Medical Center

Seoul, South Korea

Seoul National University Hospital

Seoul, South Korea

Outcomes

Primary Outcomes

time to progression

Time frame: 6 months

Secondary Outcomes

overall survival, safety, response

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.